Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 27-31.doi: 10.6040/j.issn.1671-7554.0.2017.898

Previous Articles    

Advances of endocrine therapy for hormone-receptor-positive breast cancer

LING Rui, ZHANG Juliang   

  1. Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Medical University of the Air Force, Xian 710032, Shaanxi, China)〓山〓东〓大〓学〓学〓报〓(医〓学〓版)56卷1期〓-凌瑞, 等.乳腺癌内分泌治疗的相关进展〓\=-
  • Published:2022-09-27

PDF (PC)

7

Abstract: Endocrine therapy is the mainstay treatment for hormone-receptor-positive breast cancer. Based on new evid-ences collected from clinical trials, new strategies have been available and have improved the long-term outcomes of patients, including longer endocrine treatment of early breast cancer, combined use of ovarian suppression, and so on. In parallel with expanding knowledge about the resistance mechanisms to endocrine therapy, new agents for hormone receptor-positive metastatic breast cancer continue to appear. The selective estrogen-receptor degrader, fulvestrant, and new endocrine-target combinations provide significant and clinically meaningful improvements in outcomes. This review will explore the current and investigational approaches to endocrine therapy for hormone-receptor-positive breast cancer.

Key words: Breast cancer, Hormone receptor positive, Endocrine therapy, Target therapy, Prognosis

CLC Number: 

  • R737.9
[1] Early Breast Cancer Trialists Collaborative Group(EBC-TCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
[2] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[3] Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol, 2013, 31: 5.
[4] Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2015, 372(5): 436-446.
[5] Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression(TEXT and SOFT): a combined analysis of two phase 3 randomised trials[J]. Lancet Oncol, 2015, 6(7): 848-858.
[6] Regan MM, Francis PA, Pagani O. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials[J]. J Clin Oncol, 2016, 34(19): 2221-2231.
[7] Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219.
[8] Mamounas EP, Lembersky B, Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor(AI)or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer[J]. J Clin Breast Cancer, 2006, 7(5): 416-421.
[9] Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy(DATA): a randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1502-1511.
[10] Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial(BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1). doi: 10.1093/jnci/djx134.
[11] Nabholtz JM, Buzdar A, Pollak M, et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group[J]. J Clin Oncol, 2000, 18(22): 3758-3767.
[12] Thürlimann B, Hess D, Köberle D, et al. Anastrozole(‘Arimidex’)versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET(Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability)trial[J]. Breast Cancer Res Treat, 2004, 85(3): 247-254.
[13] Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol, 2008, 26: 4883-4890.
[14] Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511.
[15] Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer(FALCON): an international, randomised, double-blind, phase 3 trial[J]. Lancet, 2016, 388(10063): 2997-3005.
[16] Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol, 2012, 30(16): 1919-1925.
[17] Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer[J]. N Engl J Med, 2012, 367(5): 435-444.
[18] Fribbens C, OLeary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25): 2961-2968.
[19] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
[20] Kornblum NS, Manola J, Klein P, et al. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor(HR)-positive, HER2-negative metastatic breast cancer(MBC)resistant to aromatase inhibitor(AI)therapy[EB/OL].[2016 SABCS S1-02]. https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf
[21] Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer(BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(7): 904-916.
[22] Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18[J]. Breast Cancer Res, 2016, 18(1): 67.
[23] Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936.
[24] Romero D. Breast cancer: MONALEESA-2 and FALCON-PFS advantage[J]. Nat Rev Clin Oncol, 2016, 13(12): 717.
[25] Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients[J]. J Glob Oncol, 2017, 3(4): 289-303.
[26] Rita N, Minetta CL, Douglas Y, et al. Permbrolizumab plus standard neoadjuvant therapy for high risk breast cancer: results from the I-SPY2 trial[EB/OL].[2017-ASCOAbs 506]. https://meetinglibrary.asco.org/record/153653/abstract.
[1] LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[2] ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96.
[3] WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112.
[4] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[5] Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[6] ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122.
[7] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[8] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29.
[9] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[10] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[11] CHU Yan, LIU Duanrui, ZHU Wenshuai, FAN Rong, MA Xiaoli, WANG Yunshan, JIA Yanfei. Expressions of DNA methyltransferases in gastric cancer and their clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 1-9.
[12] CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42.
[13] TIAN Yaotian, WANG Bao, LI Yeqin, WANG Teng, TIAN Liwen, HAN Bo, WANG Cuiyan. Machine learning models based on interpretive CMR parameters can predict the prognosis of pediatric myocarditis [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 43-49.
[14] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[15] MI Qi, SHI Shuang, LI Juan, LI Peilong, DU Lutao, WANG Chuanxin. Construction of circRNA-mediated ceRNA network and prognostic assessment model for bladder cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 94-102.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd